X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ACX-362E (ibezapolstat) is a novel antibiotic being developed as a GPSS antibacterial. It is the first of a new class of DNA polymerase IIIC inhibitors, which is being evaluated in phase 2 clinical trials for the treatment of Clostridium difficile infection.
Lead Product(s): Ibezapolstat
Therapeutic Area: Infections and Infectious Diseases Product Name: ACX-362E
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2024
Details:
ACX-362E (ibezapolstat) is a novel, orally administered antibiotic being developed as a GPSS antibacterial. It is the first of a new class of DNA polymerase IIIC inhibitor which is under phase 2 clinical development for the treatment of Clostridioides difficile infection.
Lead Product(s): Ibezapolstat
Therapeutic Area: Infections and Infectious Diseases Product Name: ACX-362E
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2024
Details:
ACX-362E (ibezapolstat) is a novel antibiotic being developed as a GPSS antibacterial. It is the first of a new class of DNA polymerase IIIC inhibitors, which is being evaluated in phase 2 clinical trials for the treatment of Clostridium difficile infection.
Lead Product(s): Ibezapolstat
Therapeutic Area: Infections and Infectious Diseases Product Name: ACX-362E
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
Ibezapolstat is a novel, orally administered antibiotic being developed as a gram-positive selective spectrum antibacterial. It is a DNA polymerase IIIC inhibitors which is being evaluated for the teatment of C. difficile infection (CDI).
Lead Product(s): Ibezapolstat
Therapeutic Area: Infections and Infectious Diseases Product Name: ACX-362E
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Details:
ACX-362E (Ibezapolstat) is a first-in-class of a new class of Pol IIIC inhibitors which is in clinical development to treat C. difficile infections or CDI.
Lead Product(s): Ibezapolstat
Therapeutic Area: Infections and Infectious Diseases Product Name: ACX-362E
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
ACX-362E (ibezapolstat) is a novel, orally administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS™) antibacterial. It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.
Lead Product(s): Ibezapolstat
Therapeutic Area: Infections and Infectious Diseases Product Name: ACX-362E
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
New data link beneficial microbiome changes in Ph2a CDI patients to earlier results from Ph1 healthy volunteers to predict potential anti-recurrence properties of ACX-362E (ibezapolstat).
Lead Product(s): Ibezapolstat
Therapeutic Area: Infections and Infectious Diseases Product Name: ACX-362E
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2022
Details:
Ibezapolstat is a first-in-class of a new class antibiotic of Pol IIIC inhibitors a Unique Gram-positive Selective Spectrum (GPSS™) Antibiotic, for Patients with Clostridioides difficile Infection.
Lead Product(s): Ibezapolstat
Therapeutic Area: Infections and Infectious Diseases Product Name: ACX-362E
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2021
Details:
The Company intends to use the net proceeds from this offering (i) to complete the Phase 2b clinical trial of ibezapolstat in patients with Clostridium difficile Infections, (ii) to complete pre-clinical development of ACX-375C.
Lead Product(s): Ibezapolstat
Therapeutic Area: Infections and Infectious Diseases Product Name: ACX-362E
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alexander Capital L.P.
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 25, 2021
Details:
Acurx Pharmaceuticals' lead candidate, ibezapolstat, recently completed a Phase 2a trial in patients with C. difficile infections, and is expected to begin a Phase 2b trial this year.
Lead Product(s): Ibezapolstat
Therapeutic Area: Infections and Infectious Diseases Product Name: ACX-362E
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alexander Capital
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 27, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
